Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation

Sponsor
Boston Children's Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01504373
Collaborator
(none)
25
1
2
115.1
0.2

Study Details

Study Description

Brief Summary

Neurally adjusted ventilatory assist (NAVA) is an FDA approved mode of mechanical ventilation. This mode of ventilation is currently in routine use in adult, pediatric and neonatal intensive care units. The electrical activity of the diaphragm, the largest muscle used during inspiration, is measured. The ventilator triggers (synchronizes patient effort) and applies proportional assistance based on measured electrical activity of the diaphragm (Edi). This electrical activity is measured through a feeding tube that also has a multiple-array esophageal electrode in it. This mode of ventilation has been proven to be equivalent to pressure support ventilation (PSV). Theoretically, the breath-to-breath control offered by NAVA may not only trigger faster and synchronize better, but provide the support deemed appropriate by the central nervous center on demand. Traditionally in the intensive care unit (ICU), pressure support is applied to subject breathing spontaneously. Pressure is set to achieve a given tidal volume. The influence of changing lung compliance not only from the lung disease itself, but the interactions of the respiratory muscles can drastically change minute ventilation and contribute to hyper- or hypoventilation. These changes are typically found on assessment of end-tidal carbon dioxide (CO2), blood gas, or oxygen saturation (SpO2) monitoring; all of which are potentially preventable if we allowed the central nervous system to control the ventilator. NAVA may allow us to couple the central nervous system (neuro-coupling) with the ventilator to provide real-time proportional assistance, reduce work of breathing and apply physiologic breathing patterns.

Condition or Disease Intervention/Treatment Phase
  • Device: Neurally Adjusted Ventilatory Assist (NAVA)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation
Study Start Date :
May 1, 2011
Anticipated Primary Completion Date :
Oct 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: NAVA-PSV

Subject will receive 4 hours of NAVA followed by 4 hours of PSV.

Device: Neurally Adjusted Ventilatory Assist (NAVA)
Subjects will be placed in the NAVA mode of ventilation.

Other: PSV-NAVA

Subject will receive 4 hours of PSV followed by 4 hours of NAVA.

Device: Neurally Adjusted Ventilatory Assist (NAVA)
Subjects will be placed in the NAVA mode of ventilation.

Outcome Measures

Primary Outcome Measures

  1. Regional distribution difference measured by electrical impedence tomography (EIT) [Change from baseline regional distribution of ventilation after the 4th hour and after 8th hour]

    Regional distribution difference measured by EIT. Area and upper to lower lung volume ratios (as determined with EIT) will be the primary data analyzed. Global and regional filling of the lung will be compared during pressure support ventilation and neurally adjusted ventilatory assist.

  2. Oxygen and metabolic cost of breathing [Change from baseline oxygen cost of breathing and carbon dioxide production after the 4th hour and after the 8th hour]

    Oxygen consumption (VO2), carbon dioxide production (VCO2), respiratory quotient (RQ), and Work of breathing (VO2/time) will be measured and compared between baseline, pressure support ventilation (PSV), and neurally adjusted ventilatory assist (NAVA) within each patient. Percent change will be compared between control (PSV) and NAVA group.

Secondary Outcome Measures

  1. Oxygenation [Monitored/recorded continuously for duration of study (8 hours total)]

    Oxygen saturation measured by pulse oxymetry (SpO2), SpO2/FiO2 ratio, non-invasive oxygen content (SpOC), and frequency of desaturations will be recorded continuously and compared between pressure support ventilation (PSV) and neurally adjusted ventilatory assist (NAVA). Although not a primary outcome measure of this study, oxygenation will allow us to further determine the safety of NAVA compared to PSV.

  2. Lung mechanics [Monitored/recorded every 30 seconds for duration of study (8 hours total)]

    Compliance, peak inspiratory pressures, positive end expiratory pressure, tidal volumes, inspired oxygen concentration, electrical activity of the diaphragm (Edi), specific Edi (ratio of tidal volume to Edi), will be measured in each patient during pressure support ventilation and neurally adjusted ventilatory assist.

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All intubated and mechanically ventilated patients in our intensive care units (ICUs) will be screened for the following inclusion criteria:
  1. Age: 1 month to 18 years.

  2. Mechanically ventilated for longer than 6 hours

  3. Either:

  4. Eligible for a spontaneous breathing mode of ventilation (not receiving chemical paralytics and has an appropriate spontaneous respiratory drive/rate given the size and condition of the patient) as determined by the team.

or

  1. Currently in the pressure support ventilation (PSV) or neurally adjusted ventilatory assist (NAVA) mode of ventilation
Exclusion Criteria:
  1. Patients in which a nasal gastric or oral gastric tube is contraindicated. Examples are but not limited to: s/p esophagus, tracheal surgery, bleeding disorders, facial trauma.

  2. Uncuffed endotracheal tube (ETT)

  3. Cervical-spine injury that prohibits rolling the patient for electrical impedance tomography (EIT) band placement.

  4. Difficult airway

  5. Congenital cyanotic heart defects

  6. Positive end expiratory pressure (PEEP) > 15 cmH2O

  7. Fractional inspired oxygen concentration (FIO2) > 0.8

  8. Peak inspiratory pressure (PIP) > 30 cmH2O

  9. Patients who are receiving chemical paralysis

  10. History of prematurity (birth at post-conceptual age <37 weeks)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children's Hospital Boston Boston Massachusetts United States 02115

Sponsors and Collaborators

  • Boston Children's Hospital

Investigators

  • Principal Investigator: John Arnold, MD, Boston Children's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
John H Arnold, Professor, Boston Children's Hospital
ClinicalTrials.gov Identifier:
NCT01504373
Other Study ID Numbers:
  • 10070341
First Posted:
Jan 5, 2012
Last Update Posted:
Mar 21, 2019
Last Verified:
Mar 1, 2019
Keywords provided by John H Arnold, Professor, Boston Children's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 21, 2019